Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 21, Issue SUPPL. 5, 2010, Pages

  Stahel, R A ^a   Weder, W ^a   Lievens, Y ^b   Felip, E ^c  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; CARBOPLATIN; CISPLATIN; DOXORUBICIN; GEMCITABINE; NAVELBINE; PEMETREXED; PLATINUM COMPLEX; RALTITREXED;

ADJUVANT THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; CYTOLOGY; DIAGNOSTIC ACCURACY; DYSPNEA; ENDOSCOPY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INTENSITY MODULATED RADIATION THERAPY; LUNG RESECTION; MALIGNANT MESOTHELIOMA; METASTASIS; PLEURA BIOPSY; PLEURA EFFUSION; PLEURA MESOTHELIOMA; PLEURECTOMY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SURGICAL APPROACH; SURGICAL TECHNIQUE; THORACOSCOPY; THORAX PAIN; TREATMENT RESPONSE;

EID: 77954317620     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq173     Document Type: Article

References (21)

1. Peto J, Decarli A, La Vecchia C et al. The European mesothelioma epidemic. Br J Cancer 1999; 86: 1970-1971.
2. Pelucchi C, Malvezzi M, La Vecchia C et al. The mesothelioma epidemic in Western Europe: an update. Br J Cancer 2004; 90: 1022-1024.
3. Robinson BW, Creaney J, Lake R et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003; 362: 1612-1616.
4. Pass HI, Wali A, Tang N et al. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg 2008; 85(1008): 265-272.
5. Fennell DA, Parmar A, Shamash J et al. Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials. J Clin Oncol 2005; 23: 184-189.
6. Edwards JG, Abrams KR, Leverment JN et al. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax 2000; 55: 731-735.
7. Weder W, Stahel RA, Bernhard J et al. Multicenter trial of neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 2007; 18: 1196-1202.
8. Krug LM, Pass HI, Rusch V et al. Multicenter trial of neoadjuvant pemetrexed plus cisplatin followed by exptrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 27 2009; 27: 3007-3013.
9. De Perrot M, Feld R, Cho J et al. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol 2009; 27: 1413-1418.
10. McAleer MF, Tsao AS, Liao Z. Radiotherapy in malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 2009; 75: 326-337.
11. Nakas A, Ucar M, Edwards JG, Waller DA. The role of video-assisted thoracoscopic pleurectomy/decortication in the therapeutic management of malignant pleural mesothelioma. Eur J Cardiothorac Surg 2008; 33: 83-88.
12. Rice DC, Stevens CW, Correa AM et al. Outcomes after extrapleural pneumonectomy and intensity-modulated radioation therapy for malignant pleural mesothelioma. Ann Thorac Surg 2007; 84: 1685-1692.
13. O'Rourke N, Garcia JC, Paul J et al. A randomized controlled trial of intervention site radiotherapy in malignant pleural mesothelioma. Radiother Oncol 2007; 84: 18-22.
14. Lee C, Bayman N, Swindell R, Faivre-Finn C. Prophylactic radiotherapy to intervention sites in mesothelioma: A systematic review and survey of UK practice. Lung Cancer 2009; 66: 150-156.
15. Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636-2644.
16. van Meerbeeck JP, Gaafar R, Manegold C et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 2005; 23: 6881-6889.
17. Castagneto B, Bota M, Aitini E et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma. Ann Oncol 2008; 19: 370-373.
18. Ceresoli GL, Zucali PA, Favaretto AG et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 2006; 24: 1443-1448.
19. Jassem J, Ramlau R, Santoro A et al. Phase III trial of pemetrexed plus best supportive care campared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 2008; 26: 1698-1704.
20. Stebbing J, Powles T, McPherson K et al. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer 2009; 63: 94-97.
21. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004; 15: 257-260.